Cargando…

All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors

Detalles Bibliográficos
Autores principales:	Mihara, K, Yoshida, T, Ishida, S, Takei, Y, Kitanaka, A, Shimoda, K, Morishita, K, Takihara, Y, Ichinohe, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916299/ https://www.ncbi.nlm.nih.gov/pubmed/27176797 http://dx.doi.org/10.1038/bcj.2016.30

Ejemplares similares

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia
por: Yoshida, Tetsumi, et al.
Publicado: (2016)

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1
por: Bhattacharyya, J, et al.
Publicado: (2012)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

CD38: T Cell Immuno-Metabolic Modulator
por: Kar, Anwesha, et al.
Publicado: (2020)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

CD38 marks the exhausted CD8(+) tissue-resident memory T cells in hepatocellular carcinoma
por: Reolo, Marie J. Y., et al.
Publicado: (2023)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

CD38 and Regulation of the Immune Response Cells in Cancer
por: Dwivedi, Sanyog, et al.
Publicado: (2021)

CD38: an ecto-enzyme with functional diversity in T cells
por: Ghosh, Alip, et al.
Publicado: (2023)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma
por: Mino, T, et al.
Publicado: (2014)

CD38-NAD(+)-Sirt1 axis in T cell immunotherapy
por: Chatterjee, Shilpak, et al.
Publicado: (2019)

Expression of CD38 in Mast Cells: Cytological and Histotopographic Features
por: Atiakshin, Dmitri, et al.
Publicado: (2021)

Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout
por: MacDonald, Robert J., et al.
Publicado: (2017)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

CD27(-)CD38(low)CD21(low) B-Cells Are Increased in Axial Spondyloarthritis
por: Wilbrink, Rick, et al.
Publicado: (2021)

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
por: Baum, Natalie, et al.
Publicado: (2021)

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
por: Peng, Ziyi, et al.
Publicado: (2023)

Responses of CD27(+)CD38(+) plasmablasts, and CD24(hi)CD27(hi) and CD24(hi)CD38(hi) regulatory B cells during primary dengue virus 2 infection
por: Lei, Chenshuang, et al.
Publicado: (2021)

Functional assessment of the cell-autonomous role of NADase CD38 in regulating CD8(+) T cell exhaustion
por: Ma, Kaili, et al.
Publicado: (2022)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
por: Grandclement, C., et al.
Publicado: (2022)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

CD19(+)CD24(hi)CD38(hi) B Cell Dysfunction in Primary Biliary Cholangitis
por: Chen, Qubo, et al.
Publicado: (2020)

CD24(+)/CD38(-) as new prognostic marker for non-small cell lung cancer
por: Karimi-Busheri, Feridoun, et al.
Publicado: (2013)

A molecular signature of dormancy in CD34(+)CD38(-) acute myeloid leukaemia cells
por: Al-Asadi, Mazin Gh., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a8va39guq0bu7rhtbqrmo330ns